Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer.
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
24
08
2020
revised:
10
01
2021
accepted:
21
04
2021
entrez:
17
6
2021
pubmed:
18
6
2021
medline:
18
6
2021
Statut:
epublish
Résumé
Liquid biopsy-based biomarkers, including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), are increasingly important for the characterization of metastatic breast cancer (MBC). The aim of the study was to explore CTCs and ctDNA dynamics to better understand their potentially complementary role in describing MBC. The study retrospectively analyzed 107 patients with MBC characterized with paired CTCs and ctDNA assessments and a second prospective cohort, which enrolled 48 patients with MBC. CTCs were immunomagnetically isolated and ctDNA was quantified and then characterized through next-generation sequencing in the retrospective cohort and droplet digital polymerase chain reaction in the prospective cohort. Matched pairs variations at baseline, at evaluation one (EV1), and at progression were tested through the Wilcoxon test. The prognostic role of ctDNA parameters was also investigated. Mutant allele frequency (MAF) had a significant decrease between baseline and EV1 and a significant increase between EV1 and progression. Number of detected alterations steadily increased across timepoints, CTCs enumeration (nCTCs) significantly increased only between EV1 and progression. MAF dynamics across the main altered genes was then investigated. Plasma DNA yield did not vary across timepoints both in the retrospective cohort and in the prospective cohort, while the short fragments fraction showed a potential role as a prognostic biomarker. nCTCs and ctDNA provide complementary information about prognosis and treatment benefit. Although nCTCs appeared to assess tumor biology rather than tumor burden, MAF may be a promising biomarker for the dynamic assessment of treatment response and resistance.
Identifiants
pubmed: 34136741
doi: 10.1200/PO.20.00345
pii: PO.20.00345
pmc: PMC8202557
doi:
Substances chimiques
Circulating Tumor DNA
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
943-952Subventions
Organisme : NCI NIH HHS
ID : R01 CA207468
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Informations de copyright
© 2021 by American Society of Clinical Oncology.
Déclaration de conflit d'intérêts
Massimo Cristofanilli Honoraria: Pfizer, Foundation Medicine Consulting or Advisory Role: Novartis, CytoDyn, Lilly, Foundation Medicine, Menarini Research Funding: Lilly, Angle, Merck No other potential conflicts of interest were reported.Massimo Cristofanilli Honoraria: Pfizer, Foundation Medicine Consulting or Advisory Role: Novartis, CytoDyn, Lilly, Foundation Medicine, Menarini Research Funding: Lilly, Angle, Merck No other potential conflicts of interest were reported.
Références
Crit Rev Oncol Hematol. 2020 Jan;145:102856
pubmed: 31884205
NPJ Precis Oncol. 2019 Jul 16;3:18
pubmed: 31341951
Cancer Lett. 2015 May 1;360(2):213-8
pubmed: 25700777
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer Treat Rev. 2019 Feb;73:73-83
pubmed: 30682661
Clin Cancer Res. 2017 Oct 1;23(19):5687-5695
pubmed: 28679771
JCO Precis Oncol. 2019;3:
pubmed: 31588418
J Clin Oncol. 2010 Jul 10;28(20):3271-7
pubmed: 20498394
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783
pubmed: 27899578
Eur J Cancer. 2021 Jan;143:147-157
pubmed: 33307492
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Ann Oncol. 2019 Jun 1;30(6):945-952
pubmed: 30860573
Clin Cancer Res. 2018 Aug 1;24(15):3528-3538
pubmed: 29776953
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
PLoS One. 2015 Oct 16;10(10):e0140712
pubmed: 26474073
Curr Treat Options Oncol. 2019 Jun 29;20(8):68
pubmed: 31256282
Breast Cancer Res. 2019 Dec 4;21(1):137
pubmed: 31801599
Oncologist. 2014 Jun;19(6):608-15
pubmed: 24794159
J Clin Oncol. 2014 Nov 1;32(31):3483-9
pubmed: 24888818
Mol Oncol. 2019 Feb;13(2):392-402
pubmed: 30516338
Science. 2013 Feb 1;339(6119):580-4
pubmed: 23372014
Crit Rev Oncol Hematol. 2019 Feb;134:39-45
pubmed: 30771872
Nat Commun. 2018 Mar 1;9(1):896
pubmed: 29497091
Int J Cancer. 2020 Mar 1;146(5):1359-1368
pubmed: 31241775
Nat Med. 2019 Dec;25(12):1928-1937
pubmed: 31768066
Breast Cancer Res. 2016 Mar 09;18(1):30
pubmed: 26961140